Would it be reasonable to begin considering GLP1 RAs or finerenone for patients with heart failure with recovered LVEF in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?

I reject the premise of the question. Patients with HFrEF who improve on medical therapy do not become HFpEF. The pathophysiology of these diseases are entirely distinct and it speaks to the limitation of EF as a categorical variable. HFrEF patients have cardiomyopathy that manifests over time as di...

The results of studies such as FINE-ARTS-HF lend promise to a space for patients with HFpEF. SELECT enrolled more of a general cardiovascular risk-enhanced population. The challenge in patients with "HFimpEF" - those that have recovered EF, is that it is difficult to understand in which category the...